增加的CCL20表达与乳腺癌的预后不佳有关
Xia Zhao1, Yanping Li, Yu Feng
1Department of Medical Oncology, Department of Surgical Breast Cancer, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Journal of the Chinese Medical Association : JCMA
|April 1, 2025
概括
乳腺癌中化学基因 (C-C动机) 配体20 (CCL20) 表达的升高与侵袭性瘤和生存率低下相关. 这一发现表明CCL20可以作为个性化治疗策略的新预后生物标志物.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 化学基因 (C-C 动机) 配体20 (CCL20) 在瘤细胞中被上调,通过创建免疫抑制微环境并增强瘤的攻击性来促进瘤的进展.
- 了解CCL20在乳腺癌中的作用对于开发向疗法至关重要.
研究的目的:
- 为了研究CCL20在乳腺癌组织中的表达.
- 评估CCL20表达与临床病理特征,表皮细胞-介质细胞过渡 (EMT) 标志物和患者结局 (总体存活率和无病存活率) 之间的关联.
主要方法:
- 对113种乳腺癌和相邻的正常组织进行了免疫组织化学染色,以评估CCL20,E-cadherin,vimentin和N-cadherin的表达.
- 统计分析包括皮尔森的千平方测试,斯皮尔曼的等级相关性测试,卡普兰-梅尔生存分析和考克斯的比例危险回归建模.
主要成果:
- 细胞质中CCL20表达在癌细胞组织 (69.9%) 与正常组织 (23%) 相比显著更高.
- CCL20表达与瘤大小,雌激素受体状态,Ki67状态,血管入侵和瘤结节转移阶段有很强的相关性.
- CCL20被确定为总生存率差的独立预测因素 (HR:3.207,P=0.027) 并与各种患者子组的不良结果有关.
结论:
- 增加CCL20表达与更具侵略性的乳腺癌表型和降低整体存活率有关.
- CCL20可能代表乳腺癌的新型独立预后生物标志物.
- 这些发现支持CCL20作为指导个性化治疗策略的生物标志物的潜在使用.
更多相关视频
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.4K
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.1K
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...